Nausea Medicine Market Research Report- Global forecast till 2023

Nausea Medicine Market Research Report- Global forecast till 2023

ID: MRFR/HC/3105-HCRR | July, 2018 | Region: Global | 110 pages | Half-Cooked Research Reports

Nausea Medicine Market Information: By Type (Antacids, Antagonists), Mode of Administration (IV, Tablets), Indication (GERD, Chemotherapy), Indication (Gastroenteritis, Gastric Ulcer), End User (Hospitals, Clinics, Pharmaceutical Companies) - Global Forecast till 2023

Market Synopsis of the Global Nausea Medicine Market


Nausea is a state of stomach distress with an urge to vomit. Common indications of nausea are motion sickness, seasickness, medication and chemotherapy. Stomach ulcers can also cause nausea. Medications and proper dietary habits can treat nausea.


Rising prevalence of gastrointestinal diseases, such as Gastroesophageal Reflux Disease (GERD), and viral gastroenteritis, and availability of a wide range of treatment options drive the market growth. Furthermore, changing lifestyle and dietary habits also influence the market.


The global nausea medicine market is expected to grow at a CAGR of 7.2% during the forecast period.


Research Methodology:

Nausea Medicine Market-


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


 


Key Players in the Global Nausea Medicine Market     


Some of the key players in this market are Merck & Co., Inc. (U.S.), Sanofi (France), TESARO, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer (U.S.), GlaxoSmithKline (U.S.), ANI Pharmaceuticals, Inc. (U.S.).


Segments                                                                                                                                            


The global nausea medicine market is segmented on the basis of type, mode of administration, indication and end user.


On the basis of type, market is segmented into antacids, antagonists, anti-anxiety drugs, steroids, Cannabinoids and Others.


Antacids are further segmented into serotonin (5-HT3) antagonists, NK-1 antagonists and dopamine antagonists.


On the basis of mode of administration, the market is segmented into IVs, tablets and others.


On the basis of indication, the market is segmented into gastroesophageal reflux disease (GERD), viral gastroenteritis, motion sickness and seasickness, medication, chemotherapy and others.


On the basis of end user, the market is segmented into hospitals, clinics, pharmaceutical companies and others.


FIGURE 1: Global Nausea Medicine Market by Region, 2016 (%)

Nausea Medicine Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Regional Analysis of the Global Nausea Medicine Market                    


America is the largest market for nausea medicine owing to rising prevalence of gastrointestinal diseases such as GERD drive the market. Furthermore, according to an article published in the “The Journal of Pediatrics” the prevalence of nausea is founding to be increasing among school going children. It also stated the Functional Gastrointestinal Disorders (FGIDs) are frequently associated with nausea. Prevalence of viral gastroenteritis is found to be increasing in the U.S., especially among the pediatric population. According to the Center for Disease Control and Prevention (CDC), each year in the United States, there are nearly 19 to 21 million cases of acute gastroenteritis. Furthermore the prevalence of acute gastrointestinal diseases is found to be high in Canada.


Europe is the second largest market for nausea medicine which exhibits growth opportunities owing to the high prevalence of nausea and vomiting among pregnant women whose population is found to be increasing. Furthermore, there is an extensive demand for the diagnosis and treatment of nausea, especially among pregnant women which will influence the market growth in Europe. Additionally, prevalence of chemotherapy induced nausea is found to be increasing steadily in many parts for the Europe in the last few years. This will further increase the demand for nausea medicine in Europe.


In Asia Pacific, the market is expected grow at the fastest rate owing to changing lifestyle and increasing geriatric population fuel the market growth. Furthermore, viral gastritis and gastric ulcer are found to be prevalent among the Asian Population.  However, presence of misbranded and spurious drugs may restrain the market growth in Asia Pacific.


The Middle East & Africa also show a steady rise in the market owing to rising prevalence of chemotherapy induced nausea.


Intended Audience



  • Nausea Medicine Manufacturers

  • Nausea Medicine Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Nausea Medicine Market, by Types

6.1 Introduction

6.2 Antacids

6.2.1 Market Estimates & Forecast, 2017-2023

6.3 Antagonists

6.3.1 Market Estimates & Forecast, 2017-2023

6.4 Anti-anxiety drugs

6.4.1 Market Estimates & Forecast, 2017-2023

6.5 Steroids

6.5.1 Market Estimates & Forecast, 2017-2023

6.6 Cannabinoids

6.6.1 Market Estimates & Forecast, 2017-2023



6.7 Others

6.7.1 Market Estimates & Forecast, 2017-2023



7. Global Nausea Medicine Market, by Mode of Administration

7.1 Introduction

7.2 IV

7.2.1 Market Estimates & Forecast, 2017-2023

7.3 Tablets

7.3.1 Market Estimates & Forecast, 2017-2023

7.4 Others

7.4.1 Market Estimates & Forecast, 2017-2023



8. Global Nausea Medicine Market, by Indication

8.1 Introduction

8.2 gastroesophageal reflux disease (GERD)

8.2.1 Market Estimates & Forecast, 2017-2023

8.3 Viral gastroenteritis

8.3.1 Market Estimates & Forecast, 2017-2023

8.4 Motion sickness and seasickness

8.4.1 Market Estimates & Forecast, 2017-2023

8.5 Medication

8.5.1 Market Estimates & Forecast, 2017-2023

8.6 Chemotherapy

8.6.1 Market Estimates & Forecast, 2017-2023

8.7 Others

8.7.1 Market Estimates & Forecast, 2017-2023

9. Global Nausea Medicine Market, by End User

9.1 Introduction

9.2 Hospital

9.2.1 Market Estimates & Forecast, 2017-2023

9.3 Clinics

9.3.1 Market Estimates & Forecast, 2017-2023

9.4 Pharmaceutical Companies

9.4.1 Market Estimates & Forecast, 2017-2023

9.5 Others

9.5.1 Market Estimates & Forecast, 2017-2023



10. Global Nausea Medicine Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 UK

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Merck & Co., Inc.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Sanofi

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 TESARO, Inc.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 F. Hoffmann-La Roche Ltd

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Pfizer

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 GlaxoSmithKline

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 ANI Pharmaceuticals, Inc.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix



LIST OF TABLES

Table 1 Nausea Medicine Industry Synopsis, 2017-2023

Table 2 Global Nausea Medicine Market Estimates and Forecast, 2017-2023, (USD Million)

Table 3 Global Nausea Medicine Market by Region, 2017-2023, (USD Million)

Table 4 Global Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 5 Global Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 6 Global Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 7 Global Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 8 North America Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 9 North America Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 10 North America Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 11 North America Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 12 US Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 13 US Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 14 US Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 15 US Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 16 Canada Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 17 Canada Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 18 Canada Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 19 Canada Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 20 South America Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 21 South America Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 22 South America Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 23 South America Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 24 Europe Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 25 Europe Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 26 Europe Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 27 Europe Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 28 Western Europe Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 29 Western Europe Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 30 Western Europe Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 31 Western Europe Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 32 Eastern Europe Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 33 Eastern Europe Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 34 Eastern Europe Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 35 Eastern Europe Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 36 Asia Pacific Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 37 Asia Pacific Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 38 Asia Pacific Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 39 Asia Pacific Nausea Medicine Market by End Users, 2017-2023, (USD Million)

Table 40 Middle East & Africa Nausea Medicine Market by Types, 2017-2023, (USD Million)

Table 41 Middle East & Africa Nausea Medicine Market by Mode of Administration, 2017-2023, (USD Million)

Table 42 Middle East & Africa Nausea Medicine Market by Indication, 2017-2023, (USD Million)

Table 43 Middle East & Africa Nausea Medicine Market by End Users, 2017-2023, (USD Million)





LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Nausea Medicine Market

Figure 3 Segmentation Market Dynamics for Nausea Medicine Market

Figure 4 Global Nausea Medicine Market Share, by Mode of Administration 2016

Figure 5 Global Nausea Medicine Market Share, by Indication 2016

Figure 6 Global Nausea Medicine Market Share, by End Users, 2016

Figure 7 Global Nausea Medicine Market Share, by Region, 2016

Figure 8 North America Nausea Medicine Market Share, by Country, 2016

Figure 9 Europe Nausea Medicine Market Share, by Country, 2016

Figure 10 Asia Pacific Nausea Medicine Market Share, by Country, 2016

Figure 11 Middle East & Africa Nausea Medicine Market Share, by Country, 2016

Figure 12 Global Nausea Medicine Market: Company Share Analysis, 2016 (%)

Figure 13 Merck & Co., Inc.: Key Financials

Figure 14 Merck & Co., Inc.: Segmental Revenue

Figure 16 Merck & Co., Inc.: Geographical Revenue

Figure 17 Sanofi: Key Financials

Figure 18 Sanofi: Segmental Revenue

Figure 19 Sanofi: Geographical Revenue

Figure 20 TESARO, Inc.: Key Financials

Figure 21 TESARO, Inc.: Segmental Revenue

Figure 22 TESARO, Inc.: Geographical Revenue

Figure 23 F. Hoffmann-La Roche Ltd: Key Financials

Figure 24 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 25 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 26 GlaxoSmithKline: Key Financials

Figure 27 GlaxoSmithKline: Segmental Revenue

Figure 28 GlaxoSmithKline: Geographical Revenue

Figure 29 Pfizer: Key Financials

Figure 30 Pfizer: Segmental Revenue

Figure 31 Pfizer: Geographical Revenue

Figure 32 Pfizer Inc: Key Financials

Figure 33 Pfizer Inc: Segmental Revenue

Figure 34 Pfizer Inc: Geographical Revenue